Chemomab Therapeutics (CMMB) Cash from Investing Activities (2017 - 2023)
Chemomab Therapeutics posted quarterly Cash from Investing Activities of $1.7 million for Q4 2023, down 81.56% year-on-year from $9.4 million in Q4 2022, and down 56.8% on a QoQ basis from $4.0 million in Q3 2023.
Chemomab Therapeutics (CMMB) has 7 years of Cash from Investing Activities data on file, last reported at $1.7 million in Q4 2023.
- For the quarter ending Q4 2023, Cash from Investing Activities fell 81.56% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2023 stood at $15.9 million (down 18.71% YoY), and the FY2025 full-year result was $5.4 million, up 134.65% from the prior year.
- Cash from Investing Activities for Q4 2023 stood at $1.7 million, down from $4.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $14.4 million in Q1 2023 and bottomed at -$20.6 million in Q2 2021.
- The 5-year median for Cash from Investing Activities is -$6500.0 (2020), against an average of -$496550.0.
- The widest annual swing landed in 2021, when Cash from Investing Activities slumped 652600.0%; it then jumped 119200.0% in 2022.
- A 5-year view of Cash from Investing Activities shows it stood at $251000.0 in 2019, then sank by 101.2% to -$3000.0 in 2020, then plunged by 652600.0% to -$19.6 million in 2021, then jumped by 147.75% to $9.4 million in 2022, then slumped by 81.56% to $1.7 million in 2023.
- The last three Cash from Investing Activities figures came in at $1.7 million (Q4 2023), $4.0 million (Q3 2023), and -$4.3 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.72 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Sep 30, 2023 | 3.99 Mn |
| Jun 30, 2023 | -4.27 Mn |
| Jun 30, 2023 | -4.27 Mn |
| Mar 31, 2023 | 14.43 Mn |
| Mar 31, 2023 | 14.43 Mn |
| Dec 31, 2022 | 9.35 Mn |
| Dec 31, 2022 | 9.35 Mn |
| Sep 30, 2022 | 6.07 Mn |
| Sep 30, 2022 | 6.07 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 1.73 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Mar 31, 2022 | 2.38 Mn |
| Dec 31, 2021 | -19.58 Mn |
| Dec 31, 2021 | -19.58 Mn |
| Sep 30, 2021 | -5.00 Mn |
| Sep 30, 2021 | -5.00 Mn |
| Jun 30, 2021 | -20.60 Mn |
| Jun 30, 2021 | -20.60 Mn |
| Mar 31, 2021 | -2,000.00 |
| Mar 31, 2021 | -2,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Sep 30, 2020 | -20,000.00 |
| Sep 30, 2020 | -20,000.00 |
| Jun 30, 2020 | -29,000.00 |
| Jun 30, 2020 | -29,000.00 |
| Mar 31, 2020 | -10,000.00 |
| Mar 31, 2020 | -10,000.00 |
| Dec 31, 2019 | 251,000.00 |
| Dec 31, 2019 | 251,000.00 |
| Sep 30, 2019 | -255,000.00 |
| Sep 30, 2019 | -255,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Mar 31, 2019 | -75,000.00 |
| Mar 31, 2019 | -75,000.00 |
| Dec 31, 2018 | -26,000.00 |
| Dec 31, 2018 | -26,000.00 |
| Sep 30, 2018 | -154,000.00 |
| Sep 30, 2018 | -154,000.00 |
| Jun 30, 2018 | -54,000.00 |
| Jun 30, 2018 | -54,000.00 |
| Mar 31, 2018 | -104,000.00 |
| Mar 31, 2018 | -104,000.00 |
| Dec 31, 2017 | -8,000.00 |
| Dec 31, 2017 | -8,000.00 |